Selank (5mg)

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a **stabilized analog of tuftsin** — a natural tetrapeptide (Thr-Lys-Pro-Arg) that is part of the IgG heavy chain. The added **Pro-Gly-Pro** sequence dramatically increases its stability and half-life. It acts through multiple mechanisms: **(1)** Increases **BDNF** levels in the hippocampus, enhancing neuroplasticity and memory. **(2)** Enhances **GABAergic transmission**, providing anxiolytic action without sedation (unlike benzodiazepines). **(3)** Stabilizes **enkephalin** levels by inhibiting their degrading enzymes (enkephalinases). **(4)** Modulates **serotonin and dopamine** — improving mood without causing euphoria. **(5)** Immunomodulatory effects via the tuftsin pathway — increasing the activity of phagocytes and NK cells, while regulating cytokine production.

• {"key": "Typical Dose", "value": "250–500mcg intranasally or subcutaneously"}
• {"key": "Frequency", "value": "1–3x/day"}
• {"key": "Storage", "value": "2–8°C after reconstitution"}

1. Clean the vial stoppers with an alcohol wipe.
2. Draw up 2mL of bacteriostatic water.
3. Inject slowly into the side wall of the vial.
4. Gently swirl until fully dissolved.
5. Store in the refrigerator (2–8°C).

• Selank (TP-7) is a synthetic heptapeptide — an analog of tuftsin (a natural immunomodulatory part of IgG) with an added Pro-Gly-Pro sequence for stability.
• Approved in Russia (2008) as an intranasal spray for anxiety disorders — developed at the Institute of Molecular Genetics (Moscow).
• Acts via multiple neurotransmitter systems: GABAergic, serotonergic, dopaminergic — providing anxiolytic action without sedation.
• Increases BDNF (Brain-Derived Neurotrophic Factor) levels, supporting neuroplasticity and memory.
• Non-addictive — does not cause dependence, tolerance, or withdrawal syndrome.

• Weeks 1–2: 250mcg, 1–2x/day (intranasally or subcutaneously).
• Weeks 3+: 500mcg, 2–3x/day, depending on response.
• Cycle: 2–4 weeks on, 1–2 weeks off.
• The intranasal route provides faster onset of action (15–30 minutes).
• Often combined with Semax for cognitive enhancement (nootropic stack).
• Break between cycles: After a cycle (2–4 weeks), a break of 2–4 weeks is recommended. Selank does not cause dependence — the break prevents potential tolerance to its anxiolytic effects and allows endogenous enkephalin balance to restore.

• Reconstituted: 2–8°C, use within 21 days.
• Lyophilized powder: 2–8°C or −20°C for long-term storage.
• Do not freeze after reconstitution.

• Non-addictive — does not cause dependence, tolerance, or withdrawal syndrome (unlike benzodiazepines).
• Does not cause sedation or drowsiness — suitable for daytime use.
• May interact with immunosuppressants due to its immunomodulatory action (tuftsin pathway).
• Intranasal action occurs within 15–30 minutes and lasts 3–6 hours.
• Use of this protocol is for informational purposes only.

1. Selank Anxiolytic Action — Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a mechanism of its anxiolytic action. Bull Exp Biol Med. 2001;131(4):315-317.
   View Source
2. Antiviral Activity — Ershov FI, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Bull Exp Biol Med. 2009;148(5):766-769.
   View Source
3. BDNF Expression — Dolotov OV, et al. Heptapeptide Selank attenuates the effects of chronic social defeat stress on depressive-like behavior and gene expression in brain. Behav Pharmacol. 2006;17(7):613-620.
   View Source
4. Gene Expression Changes — Kozlovskii II, et al. The anxiolytic effect of Selank: genome-wide expression profiling. Zh Vyssh Nerv Deiat Im I P Pavlova. 2012;62(3):365-371.
   View Source
5. Immunomodulation via Tuftsin — Semenova TP, et al. Effect of Selank on cognitive processes after damage of catecholaminergic systems. Bull Exp Biol Med. 2010;149(2):202-205.
   View Source